Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
about
In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cellsT cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemiaProducer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumorsClinical development of gene therapy: results and lessons from recent successesSignaling in Effector Lymphocytes: Insights toward Safer ImmunotherapyCurrent clinical immunotherapeutic approaches for head and neck cancerImmunotherapy for head and neck cancer: latest developments and clinical potentialNatural Killer Cells for Therapy of LeukemiaClinical manufacturing of CAR T cells: foundation of a promising therapyRole of the tumor microenvironment in mature B-cell lymphoid malignanciesCD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's LymphomasMarrow-Infiltrating Lymphocytes - Role in Biology and Cancer TherapyChronic lymphocytic leukemia: a clinical review including Korean cohortsImmunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trialsNovel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapyChimeric Antigen Receptors Modified T-Cells for Cancer TherapyAdoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advancesNovel immunotherapies in lymphoid malignanciesRadio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical ApplicationsTherapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapyCancer-treatment-induced neurotoxicity--focus on newer treatmentsAdoptive T-Cell ImmunotherapyLymphoma Immunotherapy: Current StatusTrial Watch: Adoptive cell transfer for oncological indicationsBlinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemiaT-Cell Therapy: Options for Infectious DiseasesAdoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptorsImmune Modulation in Hematologic MalignanciesTargeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to dateMelanoma: From Incurable Beast to a Curable Bet. The Success of ImmunotherapyChimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall StreetCurrent practices and reform proposals for the regulation of advanced medicinal products in CanadaThe past, present and future of immunotherapy against tumorAdoptive T-cell therapy for cancer: The era of engineered T cellsCAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in LymphomaCAR T Cell Therapy: A Game Changer in Cancer TreatmentB7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer lookCAR T cells for solid tumors: armed and ready to go?T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect
P2860
Q21559398-A1842805-9C44-40CF-A88E-C1C9754BD4B7Q24632975-B48383B5-343E-48C8-98B7-28883A9E352AQ26741260-CC2A5D13-B7C8-4E43-9670-551A73C58A1AQ26743393-D2EDF419-AD8F-45C6-8B73-CEE9C684E92FQ26744654-5B6BFC36-795E-4F7C-8FD6-0E73685A0B09Q26745411-6BC61F9A-06D0-4E79-A66C-731B9EB05565Q26745428-9CA903A3-D337-48FF-A03F-76C249D80CC1Q26745906-72F0BE7F-0418-4ED7-8248-40E32ED8C690Q26747037-AD45A0B5-7519-4F00-9B24-C64EAE63E47FQ26748775-1943991C-6A3E-440D-9022-07FFFA4C0038Q26749139-651B59B9-49F6-4C10-BEA3-B580E7CAE75EQ26749560-8784CDCD-7060-4287-961B-80AE3EA7A665Q26752467-77790839-D570-4742-872F-B2FC463A2D41Q26765115-67486061-6002-4E38-BCF5-F2F87A64A47CQ26770391-D0DD733F-0FB5-455E-9D62-EC32E40D8CA4Q26771192-228BA4AF-1A79-4760-AF34-C5682AC09251Q26773309-23DC79E9-740E-4EBE-BFDA-D01FD8282C0FQ26775720-7F75116E-3524-41D3-913D-E8E1D54B2C0DQ26777394-37B4DAFF-8E0B-47D2-8496-27AD7246F7FCQ26779221-6FE25014-EA0C-457D-B65D-C5425235FFC1Q26779938-677D8328-2CD9-4CBF-82D4-2A45F63BCEF4Q26782604-A8A7DF63-F0E6-43CE-A537-A7D840B06FBEQ26782845-48E2D142-C9FE-4F98-AADF-63ECFFDE5770Q26782902-4E22407B-833D-49FD-A0B0-BE6F600D5D10Q26785545-8AF1DF7D-7BBC-4AA6-9CA1-605C0CBA6AA7Q26785828-815FC7DB-235B-4E36-8524-29D7C208E3C6Q26786661-1CDA18D0-607A-4DCB-B65A-228DA31FBCFBQ26795540-2FD60646-5F76-411A-A703-963D1932751CQ26796307-B836C391-3ECA-4537-BCBF-518146C8F70CQ26798062-C8C7C976-A8BB-49BF-AD3F-982814F27016Q26798404-9769E2E2-1679-41DC-9A69-8AFBBDD2009AQ26799357-5F9B3F58-F9AD-4787-A0B6-31A490E43BAFQ26799720-A087E787-9247-49B2-B9EA-F504C618FF99Q26799896-AAF5BCB1-C8E5-4895-9583-6B7AEF6989C3Q26800611-B5F485D4-241A-4854-81BC-E79535F865D1Q26800814-34118C3C-2B9B-442B-9A4D-F0299BD686CFQ26822769-D85B14B4-5524-4F6D-8E44-7136832458C5Q26824446-FE8FEA28-0EF2-4A1F-AD80-0B3F81E15162Q26825489-2E1CECF2-5E03-4B6F-A041-C32CA35361D3Q26826830-8BFAA239-A4C5-4BA2-B338-833427745661
P2860
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
@ast
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
@en
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
@nl
type
label
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
@ast
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
@en
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
@nl
prefLabel
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
@ast
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
@en
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
@nl
P2093
P2860
P3181
P356
P1476
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
@en
P2093
Bruce L Levine
Carl H June
David L Porter
Michael Kalos
P2860
P304
P3181
P356
10.1056/NEJMOA1103849
P407
P5008
P577
2011-08-25T00:00:00Z